Drugs / 5-Fluorouridine
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05111860 | Nov 2022 → Aug 2024 | rectal cancer | Shanghai Minimally Invasive Surgery Center | Unknown | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05148195 | Dec 2021 → Jul 2023 | neoplasm | Jiangsu Simcere Pharmaceutical Co., Ltd. | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 5-Fluorouridine | “Bevacizumab 5mg/kg d1 Oxaliplatin 85mg/m2 d1 Calcium Folinate 400mg/m2 d1 5-fluorouridine 400mg/m2 d1 5-fluorouridine 2400mg/m2 46h q2w, 6 cycles” NCT05111860 ↗ |
| Known as | NSC-146604 | ChEMBL registry synonym — accepted as the source's own label CHEMBL54918 ↗ |
| Modality | Small molecule | — CHEMBL54918 ↗ |